Eli Lilly to buy Boston biotech Kelonia for $3.25 billion
pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene remedy maker Kelonia Therapeutics for not less than $3.25 billion, the businesses introduced Monday.
The acquisition will grant Indianapolis-based Lilly entry to Kelonia’s blood most cancers therapy known as KLN-1010 that genetically modifies sufferers’ immune cells with out requiring them to be faraway from the physique. The immune cells are reprogrammed to assault the most cancers cells in a remedy referred to as CAR-T.
“The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia’s platform,” stated Jacob Van Naarden, govt vp and president of Lilly Oncology and head of company enterprise improvement.
The partnership will place Kelonia’s therapy strategy to “broaden the reach of cell therapy beyond the current CAR-T landscape,” Kelonia CEO Kevin Friedman stated in a press release. The corporations plan to use the expertise to ultimately deal with a variety of cancers and different illnesses.
Lilly pays Kelonia $3.25 billion in money, though Kelonia may rise up to $7 billion for hitting sure scientific and business milestones, Lilly stated in a press release. Kelonia has 62 staff, most of whom are primarily based in Boston.
Lilly, booming from gross sales of its blockbuster Zepbound weight-loss injection, has been closely investing in Boston-area biotechs in current months. The Kelonia deal, which is about to shut within the second half of 2026, will mark not less than the third acquisition of a Massachusetts firm by Lilly this yr.
In February, Lilly introduced plans to purchase Watertown biotech Orna Therapeutics for up to $2.4 billion. Orna equally makes a speciality of expertise to flip a affected person’s cells into cell therapies with out eradicating them from the physique. Orna hopes to use CAR-T therapies to deal with autoimmune illnesses.
A month later, Lilly introduced it will acquire Centessa Pharmaceuticalsa narcolepsy drug maker with its US headquarters in Boston, in a deal value about $6.3 billion.
Lilly has additionally entered into quite a lot of partnerships with native corporations to develop therapies for a variety of circumstances.
boston biotech Nimbus Therapeutics is working with Lilly to develop a new oral obesity treatment in an effort to prolong Lilly’s success within the weight problems drug market. Nimbus is eligible to obtain $55 million within the close to time period and up to $1.3 billion in whole, pending sure improvement and gross sales milestones.
Lilly can be partnering with Cambridge firm Repertoire Immune Medicines to develop autoimmune illness therapies. As a part of the deal — value $85 million upfront and up to $1.84 billion whole — Repertoire will develop up to three drug candidates and Lilly will lead the candidates via scientific improvement, manufacturing, and commercialization.
In 2024, Lilly opened a $700 million research and development center within the Fort Point neighborhood of Boston. At the time, the corporate stated it deliberate to ultimately make use of about 500 employees there.
Marin Wolf may be reached at marin.wolf@globe.com.
